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Improving gene expression data interpretation by
finding latent factors that co-regulate gene
modules with clinical factors
Tianwei Yu1* and Yun Bai2*
Abstract
Background: In the analysis of high-throughput data with a clinical outcome, researchers mostly focus on genes/
proteins that show first-order relations with the clinical outcome. While this approach yields biomarkers and
biological mechanisms that are easily interpretable, it may miss information that is important to the understanding
of disease mechanism and/or treatment response. Here we test the hypothesis that unobserved factors can be
mobilized by the living system to coordinate the response to the clinical factors.
Results: We developed a computational method named Guided Latent Factor Discovery (GLFD) to identify hidden
factors that act in combination with the observed clinical factors to control gene modules. In simulation studies,
the method recovered masked factors effectively. Using real microarray data, we demonstrate that the method
identifies latent factors that are biologically relevant, and extracts more information than analyzing only the first-
order response to the clinical outcome.
Conclusions: Finding latent factors using GLFD brings extra insight into the mechanisms of the disease/drug
response. The R code of the method is available at http://userwww.service.emory.edu/~tyu8/GLFD.
Background
When high-throughput biomedical data are collected
together with outcome variables, such as treatment
groups or drug response, the focus of data analysis is
mainly selecting features that correlate with the out-
come variables and building predictive models [1,2].
Analysis at the functional group (gene set) level is also
popular because it provides mechanistic understanding
and helps reduce the search space for feature selection
[3-5]. Such methods mostly focus on finding gene sets
that show first-order relationship with the clinical out-
come variable.
The biological system is a complex network, and even
genes involved in the same biological process may not
be correlated [6-8]. Rather, more complex relations such
as dynamic correlation exist [5,9,10]. Thus we expect
the response to the clinical variable is not limited to
first-order relations, and more complex molecular
events are involved. For mechanistic studies, it may be
important to find molecular events that occur in asso-
ciation with the clinical outcome, but are not correlated
with the clinical outcome in first order.
We try to address this issue using the latent factor
model approach, which has been successful in modeling
gene regulatory networks [11]. It has been established
that the complex biological system is of modular struc-
tures [12,13], and the gene expression within a module
can be modeled reasonably well by linear functions of
the activities of the controlling factors [11,14,15]. When
using latent factor models, in some situations the latent
factors carry physical meaning, such as transcription fac-
tors (TF) in gene expression [14]. In other situations,
the latent factors may be combinations of true biological
factors, or simply some virtual controllers that reflect
the collective behavior of groups of genes/proteins [15].
Thus we do not imply causal relationships by using the
factor model, and the word “regulate” is used in a loose
manner in this manuscript.
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In the situation where observable clinical factors are
exerted on the system, we hypothesize that the biological
system would mobilize other unobserved factors to coordi-
nate the response to the clinical factors, while the response
is limited to certain relevant modules. In this manuscript,
we test this hypothesis by developing a new method
named Guided Latent Factor Discovery (GLFD) to find
such factors if they exist. The method is based on the
modular decomposition of large matrices [15]. By analyz-
ing real datasets, we demonstrate that such latent factors
do exist, and they bring extra insight into the interpreta-
tion of the data. The R code of the method is available at
http://userwww.service.emory.edu/~tyu8/GLFD.
Methods
The model
Consider a data matrix Gp × n with p genes measured in
n samples, and let Bn × m be the matrix of the scores of
m known clinical factors, e.g. treatment groups or mea-
sured responses. Our goal is to search for a group of
hidden factors, Fn × r, such that B and F jointly regulate
a gene module, with relationships represented by a lin-
ear factor model,
G(module)q×n = Lq×(m+r)[Bn×mFn×r]
T + Eq×n (1)
where q is the number of genes in the module, L is
the regulation strength matrix, and E is the residual
matrix. The number of genes, q, is usually much less
than the number of genes in the data matrix (p), as only
a fraction of genes are expected to be regulated by the
clinical factor and the latent factors. To qualify as a
module, a significant portion of the selected genes need
to have non-zero loadings on both B and F.
The procedure to find latent factors
We develop a three-step procedure to find the latent
factors.
Step 1. Finding weighted residual from each gene
In this step the residual of every gene is taken after pro-
jecting on the clinical factors. The residuals are then
weighted based on the level of association between the
gene and the clinical factors.
(a) Standardize the gene expression vectors such that
each row-vector of G is unit length. Standardize the
clinical factor matrix such that the column vectors
of B are unit length and orthogonal to each other.
This is done by using the whitening transformation.
Briefly, let Λ be the diagonal matrix of eigenvalues
of BTB, and F be the corresponding matrix of eigen
vectors as its columns, then we take B* = BFΛ-1/2.
The column vectors of B* form an orthonormal
basis and span the same subspace.
(b) Project each row vector of G, gi onto B*, and
find the projection length,
li =
√
giB ∗ B ∗′ gi ′ (2)
(c) Take the residual of each gene after projection
onto the clinical factors. Let b1, ..., bm be the column
vectors of B* ,
ri = gi −
∑m
j=1
(giβ j)β
′
j (3)
(d) This step is to assign weight to each residual
such that contribution to subspace finding is mostly
limited to genes significantly associated with the
clinical outcome. Weigh each residual vector based
on the gene’s projection length using a sigmoid
function:
r∗i =
(
1 − 1
1 + eϕ(li−δ)
)
ri (4)
where  is a large value, e.g. 100, to make the sigmoid
function approach a step function. When  is large
enough, further increasing its value has little impact on
the shape of the curve. The inflection point of the sig-
moid curve, δ, is determined by the probability of the
gene being independent from B. It is based on the fact
that the projection length of a gene independent of the
factors follows the F distribution [16].
δ =
√
mF1−α,m,n−m−1
(n − m − 1) +mF1−α,m,n−m−1
(5)
where n is the number of samples, and m is the num-
ber of factors in B. A stringent a level cutoff, e.g. 0.001
is used to account for the multiplicity caused by the
large number of genes under study. This value yields an
expected one false positive for every 1000 features. The
choice is dependent on the number of features being
studied. A more stringent cutoff needs to be used when
a higher number of features are involved. Following
eq.5, the value of δ is equal to the projection length that
corresponds to the alpha level. Residuals of genes with
projection length higher than δ receive weights close to
1, while those lower than δ receive weights close to zero.
Step 2. Searching for modules in the weighted residual
matrix
This part of the procedure is based on our method
Modular Latent Structure Analysis (MLSA) [15], which
searches for gene modules regulated by linear combina-
tions of latent factors. Briefly, MLSA seeks subspaces on
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which a portion of the row-vectors have large projection
length. It assumes no prior knowledge about module
membership. The logic behind the method is that row-
vectors belonging to a module controlled by some latent
factors should have big projection lengths on the sub-
space spanned by those latent factors. A module is
defined as a group of row-vectors whose values are con-
trolled by the same set of latent factors. Combinatorial
effects between the latent factors are necessary for the
factors to belong to the same module [15].
When the dimensionality of the subspace is known,
MLSA uses an EM-like algorithm iterating between (a)
reweighting each row-vector based on its association
with the current factor estimates, and (b) re-estimating
the latent factors of the module, until convergence. In
most cases the dimensionality is unknown, in which
case MLSA uses step forward search to determine the
dimensionality of a module. Multiple modules can be
identified from a dataset.
(a) We take the weighted residual matrix R from
Step 1, each row vector of which is the weighted
residual of a gene. We first find the length of the
longest weighted residual vector, lmax = maxi||r∗i ||,
where r∗i is the i
th row vector. We then divide the
matrix by this value,
R∗ = R/lmax (6)
This step makes the maximum row-vector length
one. It replaces the data standardization step of
MLSA, which standardizes every row vector to
length one. MLSA makes inference based on projec-
tion length. This new procedure makes sure that
contributions to latent factor finding come mostly
from genes significantly associated with the clinical
factor set B.
(b) We then iteratively find modules from R*.
(b.1) With each of the dimensionality values k = l, ...,
K, use the EM-like algorithm to find a module from
the data matrix (Algorithm 1 in [15]). The maximum
allowable dimensionality value K is taken such that no
module is likely to exceed this value. In the current
study we used K = 10, which means the maximum
allowable dimensionality of a module is 10 dimensions.
For every k, instead of randomly initiating the latent
factor estimates, we start the search from the first k
right singular vectors of the data matrix. Thus the
algorithm is less likely to converge to a local optimum.
(b.2) Compare the sizes of the modules across differ-
ent dimensionality (k), and select the module that
contains the largest number of genes. The number
of associated genes is determined by an inference
procedure that depends on the dimensionality of the
subspace, i.e. longer projection length is required for
a higher dimensional subspace [15].
(b.3) If the number of genes in the newly found
module is less than a small threshold, e.g. 10 genes,
we end the iteration. Else, for every row vector of
the matrix, we subtract its projection onto the basis
of the module. Using the new residual matrix, return
to step (b.1) to find another module.
The result from this step is a collection of latent fac-
tor sets (module basis), i.e. matrices with latent factor
scores in the column,
{
F(j)n×kj
}
, where j is the index of
modules, and kj is the dimensionality of each respective
module.
Step 3. Selecting latent factors that co-regulate genes with
clinical factors
This step uses the original expression matrix G.
(a) For the clinical factor set B* and every identified
factor set F(j), find the associated genes. This is done
by finding the projection length of each gene onto
the subspace following eq.2, and finding the signifi-
cance level using the F statistic,
F = l
2
k × n−k−11−l2 (7)
where l is the projection length of the gene, n is
the number of samples, and k is the dimensionality
of the subspace. The test statistic follows the Fk,n-k-
1 distribution. The projection length and signifi-
cance level are invariant to the rotation of the fac-
tors. We then transform the F-test p-value to false-
discovery rate (FDR), and find the genes associated
with each factor set at a certain FDR cutoff, e.g.
0.1.
(b) For every identified factor set F( j), test the
overlap between its associated genes with the
genes associated with the clinical factor set B. The
calculation takes into account of potential false
positives. Assuming the total number of genes is p,
the count of genes associated with B is m1, the
count of genes associated with F(j) is m2, the count
of overlapping genes is r, and the FDR cutoff is l,
we use m′1 = ceiling(m1(1 − λ)),
m′2 = ceiling(m2(1 − λ)), and r’ = floor(r(1 - l)2) for
the calculation of the hypergeometric p-value in a
conservative manner:
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P =
∑
l≥r′
(
p − m′1
m′2 − l
)(
m′1
l
)
(
p
m′2
) (8)
The overlap is called significant if P is smaller than a
cutoff, e.g. 0.01.
(c) If an identified factor set shows significant gene
overlapping with the clinical factor set, we further
test each of its factors separately for gene overlap-
ping with the clinical factor set, using the same
strategy as in steps (a) and (b). Only significant fac-
tors are retained.
Simulation study
We simulated data matrices with 2000 genes and 100
samples. Among the 2000 genes, module one of 200
genes were governed by the combination of a clinical
factor and some other (1 to 3) factors. Four other mod-
ules of 200 genes were each governed by 2 to 4 factors
that are independent from module one. All factor scores
were independently drawn from the standard normal
distribution. The remaining 1000 genes were pure noise
genes. Three levels of measurement noise were simu-
lated, with signal to noise ratio (S/N) equal to 0.5, 1,
and 2.
Two versions of GLFD were tested, one with exhaus-
tive factor search, the other with sequential factor
search. Two methods were used as comparison. The
first was partial least squares (PLS) regression [17]. PLS
finds a subspace to project both the genes and the out-
come variables, such that the projected genes explain
the maximum multidimensional variance of the pro-
jected outcome. The latent factors defining the subspace
were used in our comparison. The second method we
compared was supervised principal components (SPC)
[18]. SPC first extracts genes with first-order relations
with the outcome, and then finds the principal compo-
nents of the selected genes. The eigen vectors were
taken as the latent factors identified by SPC. Two var-
iants of SPC were used - (1) allowing the method to
select the cutoff using cross-validation, and (2) using the
true number of genes belonging to the module with the
clinical factor. We note that neither PLS nor SPC is for
latent factor discovery. Rather, both methods aim at pre-
dictive model building. Both PLS and SPC order the
latent factors based on their contribution to the predic-
tion of the clinical factor, and require user specification
of the dimensionality of the subspace.
For a simulated data matrix with k true latent factors
acting in combination with the clinical factor, we
selected the first k latent factors found by each method.
The selection was based on p-values for GLFD, and sim-
ply the first k factors for PLS and SPC. In the situation
that GLFD found less than k latent factors at the p-
value cutoff of 0.01, we used all the identified factors. In
order to judge the effectiveness of the methods to
recover the latent subspace, we examined how well each
true latent factor was recovered. We used the multiple
R2 value of the regression of each true latent factor
against the identified factors. At each parameter setting,
the simulation was performed 100 times. The empirical
distributions of the R2 values were plotted and com-
pared across the methods. The ideal method should
yield multiple R2 values close to one.
Results and Discussions
Simulation results
Figure 1 shows the simulation results. The two red
curves represent GLFD (solid: exhaustive factor search;
dashed: sequential factor search), and the two blue
curves represent SPC (solid: cross validation - based
cutoff selection; dashed: cutoff based on the true num-
ber of genes belonging to the module). By comparing
the two red curves, we can see that GLFD using
exhaustive factor search performed better than using
sequential factor search in the original version of
MLSA, which missed some latent factors when the sig-
nal to noise ratio was low. GLFD using exhaustive fac-
tor search clearly outperformed SPC, especially when
more latent factors regulate the gene expression
together with the clinical factor (right column). SPC
extracts global structure given the set of genes asso-
ciated with the outcome, and it uses hard cutoff to
select such genes. GLFD extracts modular structure,
and uses a model-based weighting scheme. In all simu-
lation settings, PLS trailed other methods in terms of
latent factor recovery. This is expected because PLS
seeks subspaces that best predict the clinical outcome,
while it may not be ideal for the purpose of finding
factors acting in combinations with the clinical out-
come. When the hidden truth was that no latent factor
co-regulated genes with the clinical factor, the fre-
quency of GLFD using exhaustive search identifying
false-positive latent factors was 0.05 for S/N = 0.5,
0.03 for S/N = 1, and 0.06 for S/N = 2. For GLFD
using stepwise search, the corresponding frequencies
were 0, 0.02 and 0.06 respectively. The two methods
being compared, SPC and PLS, do not have straight-
forward criteria to determine the number of latent
factors.
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Figure 1 Simulation results showing the capability of GLFD to discover latent factors, as compared with PLS and SPC. In every
simulation, 5 modules, each consisting of 200 simulated genes, were generated. The first module was governed by the clinical factor, together
with 1~3 other latent factors (columns). The other four modules were governed by 2~4 factors. All factor scores were drawn independently from
the standard normal distribution. Gaussian random noise was added to achieve different signal to noise ratios (rows). An additional 1000 pure
noise genes were generated from the standard normal distribution. Each simulation setting was repeated 100 times. The success of latent factor
recovery was evaluated by the R2 values obtained by the regression of each latent factor against the identified factors. The relative frequencies
(10 equal-sized bins between 0 and 1, equivalent to the histogram) of the R2 values are plotted.
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Methotrexate treatment response in primary acute
lymphoblastic leukemia (ALL) (GSE10255)
Downloaded from the Gene Expression Omnibus (GEO)
[19], The GSE10255 dataset is the gene expression in
primary acute lymphoblastic leukemia (ALL) associated
with methotrexate (MTX) treatment [20]. The major
clinical outcome is the reduction of circulating leukemia
cells after initial MTX treatment. We performed the
analysis by GLFD and identified two latent factors that
act in combination with the observed factor of MTX
response. When we examined the scatter plots of the
projection lengths of all genes onto the three factors
(one clinical factor and two latent factors), some inter-
esting patterns were observed (Figure 2): First, the pro-
jection length of genes onto the clinical factor is
generally low, the maximum being 0.377. This indicates
only a weak first-order transcriptional response is linked
to the clinical response. Second, the projection of genes
onto the clinical factor and the latent factors showed a
clear pattern off the axes, indicating the transcriptional
response is better interpreted as a combination of sev-
eral components.
We show the projections of genes onto the 3D sub-
space spanned by the clinical factor and the latent fac-
tors (Figure 2, inset). We performed oblique rotation
[21] on the genes with projection length > 0.4 on this
3D subspace. After rotation, the blue and green axes
each aligned to a point cloud away from the origin. The
red axis captures little information with regard to genes
having large projection lengths on the 3D subspace. In
order to shed light on the biological meaning of the
blue and green components, we resorted to gene set
analysis [3,22,23] of gene ontology biological processes
[24]. To reduce the redundancy in GO and make the
results easily interpretable, we used an organism-specific
heuristic scheme to select a subset of GO biological pro-
cess terms such that the selected terms were relatively
specific, yet not too narrow [25]. Starting from the
broad term “biological process”, the method examined
the number of human ENTREZ genes assigned to each
GO term and its descendent terms. If over 40% of the
term’s genes (70% if the term has < 500 genes) were
assigned to its descendent terms, the term was consid-
ered to be too broad and was replaced by its direct des-
cendent terms. Otherwise the term was kept in the final
selection. The method iteratively examined all biological
process terms until it reached terms with < 5 genes
assigned, which were ignored. A total of 803 GO biolo-
gical process terms were selected, which covered 10420
ENTREZ genes. The minimum number of genes
assigned to a selected term was 5, the maximum 1066,
and the median 13.
We performed gene set analysis using the method
GSA by Efron and Tibshirani [26], which handles
continuous outcomes. We used the rotated factors
themselves as the outcome variables in GSA in order to
find gene sets that were significantly associated with
them. Among the top 48 gene sets associated with the
blue factor (p ≤ 0.01), a large proportion (47.9%, com-
pared to 4.6% among all gene sets under study)
belonged to cell cycle/DNA metabolism - related pro-
cesses (Additional file 1, Table S1). This is expected
because the clinical factor itself is the reduction of cir-
culating leukemia cells after MTX treatment. Among
the top 37 gene sets associated with the green factor (p
≤ 0.01), 18.9% of them were part of the immune system
process, compared to 6.1% among all gene sets under
study (Additional file 1, Table S2). This is consistent
with MTX’s function as an immunosuppressant [27]. In
addition, 5 of the top 37 gene sets (13.5%, compared to
2.9% among all gene sets under study) were RNA meta-
bolism/transport gene sets. It has been documented that
the expression of RNA metabolism/transport genes tend
to be altered in methotrexate-resistant cells [28].
Gene set analysis on the clinical factor itself showed
enrichment of cell cycle/DNA metabolism gene sets
among the top gene sets (28.8%, compared to 47.9%
associated with the blue factor and 4.6% among all gene
sets under study; Additional file 1, Table S3). Yet the
immune system gene sets were no longer enriched in
the list (5.8%, compared to 18.9% associated with green
factor and 6.1% among all terms under study). Com-
bined with the fact that the projection lengths of genes
onto the clinical factor are relatively small (maximum is
0.377), we see that focusing only on genes/gene sets
directly correlated with the clinical factor causes loss of
power to detect significant gene expression changes in
MTX response. GLFD was able to reveal hidden factors
that act in combination with the clinical factor, and sub-
stantially enhance the data interpretation. In this dataset,
the clinical factor is an observed outcome potentially
with measurement errors. We can view the MTX
response as a combination of several underlying molecu-
lar events, the strongest of which being biological pro-
cesses related to cell reproduction and the immune
system.
As a comparison, we also applied SPC and principal
component analysis (PCA) on the dataset. PCA was
included because of its popularity in practice. The clini-
cal factor had weak impact on gene expression, hence
weak correlation with the leading PCs identified by both
SPC and PCA. For both methods, we performed oblique
rotation using the clinical factor and the first two PCs
(Additional file 1, Figures S1 ~ S4). Similar to the case
of GLFD, the projections of genes onto the three-dimen-
sional subspace were mostly explained by two latent fac-
tors. We then conducted gene set analysis by GSA on
the two factors. The first latent factor found through
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SPC showed enrichment of cell cycle-related gene sets
(18.4%, compared to 47.9% by GLFD and 4.6% among
all gene sets under study; Additional file 1, Table S4).
The second factor found through SPC showed enrich-
ment of immune system gene sets (17%, compared to
18.9% by GLFD and 6.1% in all gene sets under study;
Additional file 1, Table S5). Neither factor showed
enrichment of RNA metabolism/transport gene sets
(compared to 13.5% by GLFD and 2.9% among all gene
sets understudy). The first latent factor found through
PCA did not show clear enrichment of any major func-
tional group (Additional file 1, Table S6). The second
latent factor found through PCA showed enrichment of
immune system gene sets (12.5%, compared to 18.9% by
GLFD and 6.1% in all gene sets under study; Additional
file 1, Table S7). Overall, GLFD showed a better
Figure 2 Factors found from GSE10255 dataset. Pair-wise scatterplots of the gene expression projected onto the clinical factor and the latent
factors found by GLFD are shown. Black points correspond to genes with projection length > 0.4 onto the three dimensional subspace. Inset:
three-dimensional plot of the genes’ projection onto the subspace spanned by the clinical factor and the two latent factors. The axes were
rotated using oblique rotation. The blue and green axes align with point clouds away from the origin.
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performance on the GSE10255 dataset in terms of find-
ing relevant functional groups.
Triple negative breast cancers (TNBC) v.s. primary breast
tumors representing all subtypes (GSE18864)
The second dataset we analyzed was the GSE18864
dataset [29], which compares the gene expression of 24
sporadic triple negative breast cancer (TNBC) samples
against 51 primary breast tumor samples representing
all subtypes. TNBC is characterized by the lack of
expression of estrogen receptor (ER), progesterone
receptor (PgR), and the human epidermal growth factor
receptor 2 (ERBB2) [30]. GLFD identified two latent fac-
tors (Figure 3). As shown in the scatter plots, the shape
of the point cloud in the three-dimensional subspace is
close to elliptical. Thus we used principal component
analysis on the projections of the genes with projection
length > 0.4 on the three dimensional subspace. Rotated
factors 1 (blue) and 2 (green) captured most of the
information (Figure 3, inset).
We conducted GSA analysis to find gene sets signifi-
cantly associated with the rotated axes. 17.9% of the
gene sets associated with the blue axis (PC1) were signal
transduction pathways (Additional file 1, Table S8),
compared to 7.7% in all the gene sets under study. We
examined the gene sets for their known links to TNBC
and breast tumors in general, and found all of the seven
gene sets to be associated with breast cancer pheno-
types. Some of them have documented link to TNBC
specifically. The G-protein coupled receptor protein sig-
naling pathway (GO:0007186) involves GPR30 which
modulates the progress of estrogen-related cancers [31].
Synaptophysin, which is a member of the synaptic trans-
mission process (GO:0007268) and a marker of neu-
roendocrine (NE) differentiation, is important in breast
cancer prognostics [32]. It is also one of the markers
differentiating between basal-like breast cancer and tri-
ple negative breast cancer [33]. An associated term that
doesn’t belong to signal transduction, GO:0007416
synapse assembly, was also found to be significant.
Nuclear factor of kappaB (NF-kappaB, member of
GO:0043123) and its associated signaling pathway plays
an important role in tumor development [34]. Among
genes belonging to the biological process “signal com-
plex assembly” (GO:0007172), filamin A is important in
breast cancer cell migration [35], and Src is a potential
treatment target for TNBC [36]. EGFR and EGFR
ligands (member of GO:0007173) play a key role in
breast cancer [37] and TNBC specifically [38]. Lower
level of EGFR expression is associated reduced metasta-
sis risk in TNBC [39]. JNK pathway (GO:0007254) mod-
ulates the anticancer effect of estradiol in human breast
cancer cells [40]. RAB small GTPases (member of
GO:0007264) were found to be genetically associated
with breast cancer outcome [41]. Rho small GTPases
and their effectors (member of GO:0007264) are known
to affect the motility and metastasis of breast cancer
cells [42]. In addition to the signal transduction gene
sets, we also noticed three gene sets related to cell moti-
lity (GO:0007026, GO: 0007156, GO:0007018) were sig-
nificant (Additional file 1, Table S8). This is consistent
with the role of the two significant signal transduction
pathways that are linked to cell motility in breast cancer
(GO:0007172 and GO:0007264). In addition, the latent
factor also showed association with cell cycle gene sets
(12.8%, compared to 4.6% among all gene sets under
study; Additional file 1, Table S8), which could be
related to the different growth characteristics of TNBC
[43].
Sixteen gene sets were significantly associated with the
green axis (Additional file 1, Table S9), seven of which
were immune/cytokine/stimulus response-related genet
sets (43.8%, compared to 18.6% among all terms under
study), excluding the “sleep” process. Study by immuno-
histochemistry has documented the loss of HLA class 1
in association with breast cancer and metastasis [44].
Interleukin 6 was found to be expressed in breast cancer
tissues [45], and the blood concentration of IL6 is a
negative prognosticator for breast cancer [46]. At a
more general level, according to the Genes-to-Systems
Breast Cancer (G2SBC) Database [47], a large number
of stress response genes have altered expression in asso-
ciation with breast cancer.
Results from the GSA analysis on the clinical factor
were far from as clear-cut as those from the rotated fac-
tors (Additional file 1, Table S10). The 17 significant
gene sets included four (23.5%, compared to 18.6% over-
all) immune/cytokine/stimulus response genet sets, and
two signal transduction gene sets (11.8%, compared to
7.7% overall). The clinical factor can be seen as a projec-
tion of a much stronger signal that’s captured by the
blue axis (Figure 3, inset).
As a comparison, we also conducted similar analysis
by SPC and PCA. In this dataset, the clinical factor has
a strong impact on gene expression. For both SPC and
PCA, the subspace spanned by the first three PCs cap-
tured the clinical factor (multiple R2 > 0.8). Thus we
used the first three PCs for both methods, and per-
formed factor rotation in the same manner as GLFD
(Additional file 1, Figures S5 ~ S8). Unlike GLFD, the
projections of genes onto the three dimensional sub-
space could not be explained by two latent factors. We
performed gene set analysis using GSA on all three
latent factors for both SPC and PCA. The first latent
factor found through SPC didn’t show clear enrichment
of any major functional group (Additional file 1, Table
S11). The second latent factor showed enrichment of
cell cycle gene sets (26.5%, compared to 12.8% by GLFD
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and 4.6% among all gene sets under study; Additional
file 1, Table S12), as well as slight enrichment of
immune/cytokine/stimulus response-related genet sets
(26.5%, compared to 43.8% by GLFD and 18.6% among
all gene sets under study). The third latent factor
showed enrichment of immune/cytokine/stimulus
response-related genet sets (30.1%, compared to 43.8%
by GLFD and 18.6% among all gene sets under study;
Additional file 1, Table S13). None of the three factors
showed enrichment of signaling pathways (compared to
17.9% by GLFD and 7.7% among all gene sets under
study). For the factors found through PCA, only the sec-
ond factor showed enrichment of cell cycle gene sets
(30%, compared to 12.8% by GLFD and 4.6% among all
gene sets under study; Additional file 1, Tables
S14~S16). It is notable that the most prominent factor
Figure 3 Factors found from GSE18864 dataset. Pair-wise scatterplots of the gene expression projected onto the clinical factor and the two
latent factors found by GLFD are shown. Black points correspond to genes with projection length > 0.4 onto the three dimensional subspace.
Inset: three-dimensional plot of the genes’ projection onto the subspace spanned by the clinical factor and the two latent factors. The axes were
rotated using PCA. Blue: first PC, green: second PC, red: third PC.
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found by both SPC and PCA weren’t clearly associated
with any functional category. A possible explanation is
that both methods captured vague global information in
the data. In terms of finding relevant functional cate-
gories, SPC, which was competitive in some of the simu-
lation settings, was close to GLFD, while PCA lagged
behind.
In the real data analysis, we used two datasets that
were generated from well-characterized diseases and
treatment. The results confirmed the biological rele-
vance of the findings by GLFD. In less well-character-
ized datasets, GLFD can help answer the question
“What else has happened besides the differential expres-
sion?”. The latent factors that GLFD seeks to identify
are orthogonal to the clinical factors. This means they
may not contribute to the prediction of the clinical out-
come. However, in many situations, the goal of the
study is to gain biological insight into the mechanisms
of diseases. In addition, as demonstrated in the case of
the MTX response data, the clinical outcome itself may
be measured using a traditional marker, possibly with
measurement error. In such situations, finding latent
factors helps to better interpret the data and generate
hypotheses of potential pathways that are activated
together with the clinical outcome. GLFD uses weighted
residuals of genes after projecting onto the clinical fac-
tors. Modular decomposition of a large matrix amounts
to search in a very high dimensional space [15]. It is dif-
ficult computationally to reach the global optimum. The
use of weighted residuals greatly reduces the search
space by focusing the downstream steps on genes that
are significantly associated with the clinical factors. In
addition, it guarantees orthogonality between the identi-
fied factors and the clinical factors.
An alternative approach is to apply MLSA directly to
the expression matrix, and then select factors that co-
regulate genes with the clinical factor. We tested the
idea on the two datasets. The post-processing became
more involving as a much larger number of factors were
identified, and they were not orthogonal to the clinical
factors. We used a heuristic approach to address this
issue. We forced the identified factors to be orthogonal
to the clinical factor by subtracting their projection onto
the clinical factor. We then applied the same factor
selection procedure as in Step 3 of the Methods section.
For both the GSE10255 dataset and the GSE18864 data-
set, the alternative approach selected the same number
of factors as GLFD. We applied the same rotation pro-
cedures for each dataset respectively as described above,
and tested the latent factors for gene set association by
GSA (Additional file 1, Figures S9 ~ S12). For the
GSE10255 dataset, the first latent factor showed enrich-
ment of immune system gene sets (20%, compared to
18.9% by GLFD and 6.1% among all gene sets under
study; Additional file 1, Table S17), and the second
latent factor showed enrichment of cell cycle gene sets
(32.9%, compared to 47.9% by GLFD and 4.6% among
all gene sets under study; Additional file 1, Table S18).
Neither factor showed enrichment of RNA metabolism/
transport gene sets (compared to 13.5% by GLFD and
2.9% among all gene sets under study). For the
GSE18864 dataset, the first latent factor showed enrich-
ment of cell cycle gene sets (31.4%, compared to 12.8%
by GLFD and 4.6% among all gene sets under study;
Additional file 1, Table S19), and the second latent fac-
tor showed enrichment of signaling gene sets (12.9%,
compared to 17.9% by GLFD and 7.7% among all gene
sets under study; Additional file 1, Table S20). Neither
factor showed enrichment of immune/cytokine/stimulus
response-related genet sets (compared to 43.8% by
GLFD and 18.6% among all gene sets under study). The
results of the comparisons showed that while the alter-
native approach required more post-processing, its per-
formance was not as good as GLFD in terms of finding
relevant functional categories.
The main purpose of GLFD is to identify the subspace
governed by both the clinical factor(s) and latent factors.
Genes showing large projections onto the subspace are
considered to be in a clinically relevant module. For the
latent factors to belong to the module, a significant
number of the genes in the module need to be regulated
by both the clinical factor(s) and the latent factors. In
the search of latent factors, GLFD maintains the ortho-
gonality between the observed clinical factor(s) and the
latent factors, as well as between the latent factors.
Once the subspace is determined, there are several ways
to handle the factors - (1) keep the identified factors, (2)
rotate the factors while maintaining orthogonality, (3)
rotate the factors without maintaining orthogonality,
and (4) rotate only the latent factors with/without
orthogonality constraint. As the dimensionality is drasti-
cally reduced, the projection of the entire data onto the
subspace can be visualized to help the user make a deci-
sion. Similar to the situation of traditional factor analy-
sis, the choice of rotation depends on the data structure
and user interpretation, which is beyond the scope of
the GLFD method.
Conclusions
In summary, we developed a new approach to interpret
high throughput data and the associated algorithm
based on modular matrix decomposition. The method is
effective in bringing more insights into the data by find-
ing latent factors that co-regulate genes with observed
clinical factors. It can be used as an explorative tool for
data interpretation and hypothesis generation.
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